AIM
CRSP icon

Axiom Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Axiom Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.9K Buy
+1,520
New +$80.1K 0.06% 173
2021
Q2 		– Sell
-2,826
Closed -$344K – 165
2021
Q1 		$344K Buy
+2,826
New +$427K 0.28% 86

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Axiom Investment Management's CRSP Position: Q2 2026 in Review

Axiom Investment Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 1,520 shares worth $82.9K. The stake represents 0.06% of the portfolio and ranks #173 among its holdings. This is a return to the name: Axiom Investment Management previously reported a position in CRSP as recently as Q1 2021.

Axiom Investment Management first reported a position in CRSP in Q1 2021 and has held it in 2 quarters since. The position peaked at $344K in Q1 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Axiom Investment Management held 1,520 shares of CRISPR Therapeutics worth $82.9K as of Q2 2026.
  • CRISPR Therapeutics was a new Axiom Investment Management position in Q2 2026.
  • CRISPR Therapeutics made up 0.06% of Axiom Investment Management's portfolio in Q2 2026, its #173 holding.
  • Axiom Investment Management first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • Axiom Investment Management's CRISPR Therapeutics position peaked at $344K in Q1 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.